CYTOSORBENTS CORPORATION (CTSO) Operating margin 2016–2025
CYTOSORBENTS CORPORATION (CTSO) operating margin by fiscal year — reported operating income divided by reported revenue.
-39.8%FY2025 · since FY2016: -120.6% → -39.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -39.8% | +6.4 pp |
| FY2024 | -46.2% | +56.6 pp |
| FY2023 | -102.8% | -11.9 pp |
| FY2022 | -90.9% | -38.2 pp |
| FY2021 | -52.7% | -27.4 pp |
| FY2020 | -25.3% | +50.8 pp |
| FY2019 | -76.0% | -6.8 pp |
| FY2018 | -69.3% | -4.3 pp |
| FY2017 | -65.0% | +55.7 pp |
| FY2016 | -120.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTSO financial trends
CTSO RevenueCTSO Net incomeCTSO Net marginCTSO Gross profitCTSO Gross marginCTSO Operating incomeCTSO Operating cash flowCTSO Free cash flowCTSO Capital expendituresCTSO Return on equityCTSO Stock buybacksCTSO Dividends paidCTSO Total assetsCTSO Total liabilitiesCTSO Shareholders’ equityCTSO overview →